Accendra Health, Inc. ACH R2K

Healthcare · Medical Distribution · United States

https://www.accendrahealth.com

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.

Market & Price

Market Cap

$217.50M

Current Price

$2.84

High / Low (52W)

$9.42 / $1.91

Beta

1.70

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

4.13

PEG Ratio

0.70

Book Value

$-6.07

Price to Book

-0.47

P/S

0.08

EV/EBITDA

6.33

Dividend Yield

Profitability & Returns

ROCE

0.35%

ROE

ROA

1.55%

Profit Margin

-39.84%

Op Margin

-1.02%

EPS (Latest Qtr)

$-0.08

EPS (TTM)

$-1.37

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.37

Current Ratio

0.49

Debt

$2.17B

Total Assets

$2.45B

Current Assets

$547.87M

Working Capital

$-399.20M

Ownership

Promoter Holding

7.71%

Chg in Prom Hold

-0.00%

FII / Inst Holding

85.95%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$2.05B

Total Revenue (TTM)

$2.72B

EBITDA

$323.73M

Free Cash Flow

$650.28M

Operating Cash Flow

$-116.80M

Shares Outstanding

76.58M

Gross Margin

45.95%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-34.78%

Profit 5Y

-1,672.00%

Revenue (YoY)

-6.80%

Earnings (YoY)

PROS

Generates positive free cash flow.

CONS

Revenue declined at -34.8% CAGR over 5 years.
Earnings shrank at -1672.0% CAGR over 5 years.
Trading 69.8% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ACH Accendra Health, Inc. R2K	2.84	-	$217.50M	-	0.35%	-	-34.78%	-1,672.00%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	2.33B	2.37B	2.46B	2.46B	2.35B	2.38B	2.29B	2.12B	1.81B	2.19B	2.33B	2.49B	2.50B	2.41B	2.50B	2.50B	2.52B	2.56B	2.59B	2.61B	660.40M	-	-	673.88M	681.92M	697.26M	708.97M	627.78M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	354.64M	357.31M	375.07M	385.71M	349.75M
Gross Profit	273.33M	281.19M	282.27M	292.48M	297.60M	298.34M	306.35M	296.64M	299.42M	296.27M	281.18M	273.53M	301.94M	324.69M	324.99M	352.57M	276.62M	286.52M	280.62M	268.56M	269.41M	344.34M	442.75M	400.07M	328.84M	373.45M	532.50M	513.28M	497.31M	519.43M	538.50M	535.53M	544.15M	-	-	319.24M	324.60M	322.20M	323.26M	278.03M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	262.37M	267.85M	265.84M	271.50M	255.23M
Operating Income	49.22M	46.28M	37.10M	35.38M	40.98M	47.86M	53.57M	44.97M	52.05M	53.57M	35.52M	32.84M	29.67M	24.22M	-172.05M	21.36M	16.60M	15.90M	26.11M	10.76M	22.20M	75.55M	146.69M	96.88M	62.88M	61.06M	75.08M	60.25M	9.81M	10.84M	23.84M	9.70M	16.92M	-	-	56.87M	56.75M	56.36M	51.76M	22.80M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	61.72M	18.71M	89.49M	49.83M	77.84M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.21M	26.01M	29.03M	27.93M	32.35M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.40M	-84.95M	-3.63M	-7.97M	-16.25M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.59M	-1.13M	1.97M	1.47M	-9.78M
Net Income	27.97M	25.48M	19.88M	-	-	-	28.18M	24.14M	27.72M	29.83M	18.79M	20.14M	10.87M	8.15M	-182.78M	-565.00K	-14.10M	-10.48M	1.22M	-11.32M	-55.63M	46.08M	69.59M	65.90M	44.13M	39.28M	28.60M	12.50M	-24.42M	-28.24M	-6.43M	-21.89M	-31.91M	-	-	-24.98M	-869.06M	-150.28M	-56.33M	-6.47M
Diluted EPS	0.44	0.41	0.32	0.11	0.30	0.39	0.45	0.39	0.45	0.48	0.31	0.33	-	-	-	-	-	-	-	-	-0.91	0.76	0.98	0.87	0.58	0.52	0.37	0.16	-0.32	-0.37	-0.08	-0.29	-0.42	-	-3.84	-0.32	-11.30	-1.94	-	-0.08

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	9.72B	9.32B	9.42B	9.21B	8.48B	-	9.96B	2.55B	2.68B	2.76B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.13B	1.34B	1.40B	1.47B
Gross Profit	741.11M	814.39M	807.73M	857.54M	924.65M	1.12B	1.17B	1.21B	1.19B	1.17B	1.07B	1.13B	1.28B	-	1.83B	1.22B	1.28B	1.29B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.55B	1.00B	1.08B	1.07B
Operating Income	180.72M	201.28M	195.94M	203.51M	196.75M	198.08M	159.54M	200.36M	199.60M	89.25M	-352.35M	73.15M	204.12M	-	276.78M	215.36M	198.04M	221.74M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	368.45M	342.40M	-41.04M	219.75M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	128.89M	116.77M	107.57M	107.18M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.89M	15.27M	-329.88M	-101.95M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11.50M	6.36M	20.85M	729.00K
Net Income	93.33M	104.66M	110.58M	115.20M	109.00M	110.88M	66.50M	103.41M	108.79M	72.79M	-437.01M	-62.37M	29.87M	-	22.39M	-41.30M	-362.69M	-1.10B
Diluted EPS	1.50	1.67	1.75	1.81	1.72	1.76	1.06	1.65	1.76	-	-	-1.03	0.47	-	0.29	-0.54	-4.73	-14.31
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	12.10M	12.00M	13.00M	13.00M	-

Compounded Sales Growth

5 Years:	-34.78%
1 Year:	-6.80%

Compounded Profit Growth

5 Years:	-1,672.00%
1 Year:	-

Stock Price Performance

1 Year:	-56.97%
6 Months:	+3.27%
3 Months:	+17.36%
1 Month:	-18.62%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	1.75B	1.82B	1.95B	2.21B	2.32B	2.74B	2.77B	2.72B	3.38B	3.77B	3.64B	3.34B	-	5.39B	5.09B	4.66B	2.45B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.30B	2.10B	2.02B	547.87M
Cash & Equivalents	10.39M	7.89M	96.14M	159.21M	135.94M	97.89M	101.91M	56.77M	161.02M	185.49M	104.52M	66.31M	67.03M	83.06M	-	69.47M	243.04M	27.57M	281.99M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.33B	1.11B	67.58M	74.44M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	763.50M	598.26M	218.27M	95.91M
Total Liabilities	-	-	977.91M	964.52M	1.03B	1.24B	1.30B	1.74B	1.78B	1.76B	2.36B	3.26B	3.18B	2.62B	-	4.44B	4.17B	4.07B	2.91B
Current Liabilities	-	-	700.12M	694.48M	732.37M	925.64M	990.21M	966.58M	1.06B	1.03B	1.31B	1.47B	1.42B	1.35B	-	1.57B	1.89B	1.85B	947.08M
Long Term Debt	-	-	-	209.10M	212.68M	215.38M	212.79M	608.55M	568.50M	564.58M	900.74M	1.65B	1.51B	986.02M	-	2.48B	1.89B	1.80B	1.80B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.72B	2.32B	1.93B	2.12B
Total Equity	614.36M	689.05M	769.18M	857.52M	918.09M	972.53M	1.02B	990.84M	-	-	1.02B	518.42M	462.15M	712.05M	-	945.60M	924.17M	586.36M	-460.98M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	76.28M	76.55M	77.20M	76.39M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	140.55M	-3.76M	270.24M	187.69M	56.77M	115.59M	166.09M	339.22M	-	325.01M	740.71M	161.50M	-101.79M
Investing Cash Flow	-	-	-	-	-	-57.08M	-317.25M	-36.47M	-24.75M	-416.64M	-815.83M	-51.90M	80.07M	-	-1.80B	-137.25M	-116.53M	144.42M
Financing Cash Flow	-	-	-	-	-	-81.98M	278.56M	-124.88M	-142.70M	272.81M	701.07M	-130.20M	-379.39M	-	1.50B	-417.33M	-267.60M	188.08M
Capital Expenditure	-17.67M	-19.75M	-31.22M	-24.98M	-9.83M	-28.12M	-48.42M	-20.53M	-20.30M	-34.61M	-44.87M	-42.42M	-50.42M	-	-166.58M	-178.53M	-182.66M	-201.32M
Free Cash Flow	-	-	-	-	-	112.44M	-52.19M	249.71M	167.39M	22.16M	70.72M	123.67M	288.80M	-	158.42M	562.18M	-21.17M	-303.12M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.64M	186.13M	-222.64M	230.71M
Share Buybacks	-	-	-	16.12M	15.00M	18.88M	9.93M	20.00M	71.03M	5.00M	0	-	-	-	-	-	-	10.18M
Dividends Paid	33.05M	38.37M	44.78M	50.91M	55.68M	60.73M	63.10M	63.65M	63.38M	63.15M	48.20M	5.23M	648.00K	731.00K	0	0	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	12.2%	12.6%	11.4%	12.3%	15.1%	-	18.3%	47.7%	47.8%	46.7%
Operating Margin %	-	-	-	-	-	-	-	-	2.1%	1.0%	-3.7%	0.8%	2.4%	-	2.8%	8.4%	7.4%	8.0%
Net Margin %	-	-	-	-	-	-	-	-	1.1%	0.8%	-4.6%	-0.7%	0.4%	-	0.2%	-1.6%	-13.5%	-39.8%
ROE %	13.5%	13.6%	12.9%	12.5%	11.2%	10.8%	6.7%	-	-	7.2%	-84.3%	-13.5%	4.2%	-	2.4%	-4.5%	-61.9%	238.8%
ROCE %	-	19.2%	17.4%	16.8%	15.3%	14.9%	9.0%	11.7%	11.9%	4.3%	-15.3%	3.3%	10.3%	-	7.2%	6.7%	7.1%	14.7%

Shareholding Pattern

Insiders

7.71%

Institutions

85.95%

Public Float

93.13%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Coliseum Capital Management, Llc	17.11%	13.10M	$37.21M
2	Blackrock Inc.	6.84%	5.24M	$14.87M
3	Charles Schwab Investment Management, Inc.	4.75%	3.64M	$10.32M
4	Bank of America Corporation	4.45%	3.41M	$9.68M
5	Invenomic Capital Management, LP	4.40%	3.37M	$9.57M
6	Shaw D.E. & Co., Inc.	4.32%	3.31M	$9.40M
7	Vanguard Capital Management LLC	4.29%	3.28M	$9.32M
8	Vanguard Portfolio Management LLC	3.46%	2.65M	$7.53M
9	Dimensional Fund Advisors LP	3.40%	2.61M	$7.40M
10	Geode Capital Management, LLC	2.40%	1.84M	$5.21M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ACH

No recent headlines available.

ACH · Healthcare